From: Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma
Name | Origin | Xenograft origin | Treatment | Number of mice | Median survival in days | Survival enhancement after RT (%) | p-valuea | Mean TGD in days (%) | Quadrupling Time of RT vs NT p-valueb |
---|---|---|---|---|---|---|---|---|---|
CB193 | glioma grade III | Cell line | NT | 9 | 42 [37;46] | 226 | < 0.001 | 66 ± 13 (351) | < 0.01 |
RT | 6 | 95 [88;140] | |||||||
SF763 | glioblastoma | Cell line | NT | 12 | 39 [32;52] | 226 | < 0.01 | 54 ± 15 (399) | < 0.001 |
RT | 7 | 88 [81;102] | |||||||
SF767 | glioblastoma | Cell line | NT | 8 | 77 [65;80] | 168 | < 0.001 | 52 ± 7 (215) | < 0.001 |
RT | 12 | 129 [101;140] | |||||||
T98G | glioblastoma | Cell line | NT | 8 | 20 [16;23] | 175 | < 0.001 | 15 ± 5 (259) | < 0.01 |
RT | 8 | 35 [33;37] | |||||||
U87MG | glioblastoma | Cell line | NT | 6 | 29 [22;30] | 134 | < 0.001 | 11 ± 1 (149) | < 0.01 |
RT | 10 | 39 [37;41] | |||||||
U118MG | glioblastoma | Cell line | NT | 6 | 38 [23;49] | 179 | 0.059 | 26 ± 4 (278) | < 0.01 |
RT | 9 | 68 [51;79] | |||||||
GBM-1-HAM | glioblastoma | Patient sample | NT | 13 | 16 [14;18] | 319 | < 0.001 | 19 ± 4 (320) | < 0.001 |
RT | 9 | 51 [37;72] | |||||||
GBM-14-CHA | glioblastoma | Patient sample | NT | 6 | 16 [14;19] | 250 | < 0.001 | 2 ± 1 (115) | ns |
RT | 10 | 40 [28;44] | |||||||
GBM-14-RAV | glioblastoma | Patient sample | NT | 6 | 29 [24;38] | 259 | < 0.001 | 37 ± 5 (386) | < 0.01 |
RT | 10 | 75 [61;82] | |||||||
ODA-17-GIR | glioma grade III | Patient sample | NT | 6 | 19 [14;25] | 405 | < 0.001 | 55 ± 3 (715) | < 0.01 |
RT | 8 | 77 [65;79] | |||||||
ODA-4-GEN | glioma grade III | Patient sample | NT | 6 | 26 [20;28] | 215 | < 0.001 | 33 ± 3 (462) | < 0.01 |
RT | 8 | 56 [51;63] |